Clinical Trial Update: Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab. [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating mobile devices to detect early pneumonitis in unresectable Stage III non-small cell lung cancer patients treated with durvalumab w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Unresectable Stage III NSCLC | Phase 4 | Status: TERMINATED | Results posted: 2023-06-22